- Company
- Julien Samson will be relocating to the UK headquarters
- by Eo, Yun-Ho Sep 18, 2020 06:29am
- According to related industries, GSK Korea held a town hall meeting on the 16th, and Julien Samson, announced that his current term of office as the head of the Korean subsidiary will be ended in this November. Julien Samson will be relocating to the UK headquarters in December. The successor to lead the Korean subsidiary was Robert Kempt
- Policy
- Sinopharm COVID-19 vaccine, not considered to be introduced
- by Kim, Jung-Ju Sep 18, 2020 06:29am
- Although China is in the midst of developing COVID-19 treatments and vaccines, the government said that it has no plans to import domestically unless the safety and efficacy of these products are secured. Far from being included in the plan to secure 30 million domestic patients, it means that domestic introduction itself is impossible.
- Product
- “MA and marketer need experience, analytic mind, acumen”
- by Kim, Min-Gun Sep 18, 2020 06:29am
- “For a Market Access (MA) specialist, the most important skill set is to analyze the clinical trial data and to recreate them as a valuable message. They need to find any missing data required for pharmaceutical reimbursement review, and prepare the evidences prior to the review, if need be. If you are a pharmacy school student and want to beco
- Company
- “APAC countries need NPM in the age of expensive drugs”
- by Eo, Yun-Ho Sep 17, 2020 06:30am
- A pharmaceutical industry expert suggested Asian-Pacific countries should also take novel payment models into account in this age of high-cost drugs. On Sept. 16, the ‘International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Asia Pacific 2020’ hosted a web session on ‘ICER Threshold for Innovative Medicines &8211; Ha
- Policy
- Jeil, started commercialization of JLP-1401
- by Lee, Tak-Sun Sep 17, 2020 06:29am
- Jeil has begun commercializing a high blood pressure-hyperlipidemia three-drug, credit-quantity formulation. It is a formulation that combines Telmisartan-Amlodipine-Rosuvastatin, and is known as a new product of Telmiduo Plus, which Jeil is already launching. The MFDS approved the phase I clinical trial protocol of JLP-1401 submitted b
- Company
- Hanmi promotes clinical use of Keytruda & FLX475
- by Sep 17, 2020 06:29am
- Hanmi is entering a phase II clinical trial that uses a combination of CCR4 target oral immuno-cancer drug (FLX475), which is being developed in Korea, and MSD's immuno-cancer drug Keytruda (Pembrolizumab). To this end, Hanmi announced on the 15th that it has signed a contract with MSD to supply Keytruda for clinical cooperation and clinic
- Company
- Sanofi, to supply flu vaccine, Vaxigriptetra nationwide
- by Sep 17, 2020 06:29am
- Sanofi Pasteur (CEO Pascal Robin) announced on the 15th that it has supplied the flu vaccine 'Vaxigriptetra' nationwide. Sanofi Pasteur said that this year's flu vaccine is included in the NIP, and as the number of recipients expanded due to the spread of COVID-19, patients in need of flu prevention can receive the vaccine on time. Vaxigr
- Company
- Growth hormone market fluctuates with Pfizer’s supply issue
- by Kim, Jin-Gu Sep 17, 2020 06:29am
- The growth hormone injection market generating annual sales of 150 billion won had a fluctuating sales rank in the first half of the year. While LG Chem is still leading the market, Pfizer in the second place was dropped to the fifth place due to its global supply suspension. On the contrary, LG Chem, Dong-A ST and Novo Nordisk boosted their
- Company
- Where can clinics get flu vaccines?
- by Sep 16, 2020 06:26am
- "All pharmaceutical companies say they don't have flu vaccine stock. I am already worried because the quantity I received from the public health center is small." A Doctor of Clinic A in Seoul said in this way that he called all of the sales staff at pharmaceutical companies that supply flu vaccines, but said it was hard to get supplies.
- Company
- Talks on new payment system in the age of high-cost drugs
- by Eo, Yun-Ho Sep 16, 2020 06:25am
- Pharmaceutical experts are initiating talks on setting adequate Incremental Cost-Effectiveness Ratio (ICER) threshold to design a new payment model fitting the age of high-cost drug. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Asia Pacific 2020, convened online from Sept. 14 through 16, would be hosting
